1
|
"Betwixt Mine Eye and Heart a League Is Took": The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy. Int J Mol Sci 2020; 21:ijms21196997. [PMID: 32977524 PMCID: PMC7582534 DOI: 10.3390/ijms21196997] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 09/17/2020] [Accepted: 09/21/2020] [Indexed: 12/19/2022] Open
Abstract
The ultimate goal of precision disease modeling is to artificially recreate the disease of affected people in a highly controllable and adaptable external environment. This field has rapidly advanced which is evident from the application of patient-specific pluripotent stem-cell-derived precision therapies in numerous clinical trials aimed at a diverse set of diseases such as macular degeneration, heart disease, spinal cord injury, graft-versus-host disease, and muscular dystrophy. Despite the existence of semi-adequate treatments for tempering skeletal muscle degeneration in dystrophic patients, nonischemic cardiomyopathy remains one of the primary causes of death. Therefore, cardiovascular cells derived from muscular dystrophy patients' induced pluripotent stem cells are well suited to mimic dystrophin-associated cardiomyopathy and hold great promise for the development of future fully effective therapies. The purpose of this article is to convey the realities of employing precision disease models of dystrophin-associated cardiomyopathy. This is achieved by discussing, as suggested in the title echoing William Shakespeare's words, the settlements (or "leagues") made by researchers to manage the constraints ("betwixt mine eye and heart") distancing them from achieving a perfect precision disease model.
Collapse
|
2
|
Agüera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Peña J. Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE 2019; 8:23-31. [PMID: 30719380 PMCID: PMC6349589 DOI: 10.1016/j.jshs.2017.05.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 01/31/2017] [Accepted: 03/26/2017] [Indexed: 06/09/2023]
Abstract
PURPOSE The objective of the present study was to determine whether a denervated muscle extract (DmEx) could stimulate satellite cell response in denervated muscle. METHODS Wistar rats were divided into 4 groups: normal rats, normal rats treated with DmEx, denervated rats, and denervated rats treated with DmEx. The soleus muscles were examined using immunohistochemical techniques for proliferating cell nuclear antigen, desmin, and myogenic differentiation antigen (MyoD), and electron microscopy was used for analysis of the satellite cells. RESULTS The results indicate that while denervation causes activation of satellite cells, DmEx also induces myogenic differentiation of cells localized in the interstitial space and the formation of new muscle fibers. Although DmEx had a similar effect in nature on innervated and denervated muscles, this response was of greater magnitude in denervated vs. intact muscles. CONCLUSION Our study shows that treatment of denervated rats with DmEx potentiates the myogenic response in atrophic denervated muscles.
Collapse
Affiliation(s)
- Eduardo Agüera
- Department of Neurology, Maimonides Institute for Biomedical Research IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| | - Salvador Castilla
- Department of Critical Care and Emergency, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| | - Evelio Luque
- Department of Morphological Sciences, Section of Histology, Faculty of Medicine and Nursing, Maimonides Institute for Biomedical Research IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| | - Ignacio Jimena
- Department of Morphological Sciences, Section of Histology, Faculty of Medicine and Nursing, Maimonides Institute for Biomedical Research IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| | - Ignacio Ruz-Caracuel
- Department of Morphological Sciences, Section of Histology, Faculty of Medicine and Nursing, Maimonides Institute for Biomedical Research IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| | - Fernando Leiva-Cepas
- Department of Morphological Sciences, Section of Histology, Faculty of Medicine and Nursing, Maimonides Institute for Biomedical Research IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| | - José Peña
- Department of Morphological Sciences, Section of Histology, Faculty of Medicine and Nursing, Maimonides Institute for Biomedical Research IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain
| |
Collapse
|
3
|
Limongelli G, D’Alessandro R, Maddaloni V, Rea A, Sarkozy A, McKenna WJ. Skeletal muscle involvement in cardiomyopathies. J Cardiovasc Med (Hagerstown) 2013; 14:837-61. [DOI: 10.2459/jcm.0b013e3283641c69] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
4
|
Hirt-Burri N, de Buys Roessingh AS, Scaletta C, Gerber S, Pioletti DP, Applegate LA, Hohlfeld J. Human muscular fetal cells: a potential cell source for muscular therapies. Pediatr Surg Int 2008; 24:37-47. [PMID: 17962961 DOI: 10.1007/s00383-007-2040-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Myoblast transfer therapy has been extensively studied for a wide range of clinical applications, such as tissue engineering for muscular loss, cardiac surgery or Duchenne Muscular Dystrophy treatment. However, this approach has been hindered by numerous limitations, including early myoblast death after injection and specific immune response after transplantation with allogenic cells. Different cell sources have been analyzed to overcome some of these limitations. The object of our study was to investigate the growth potential, characterization and integration in vivo of human primary fetal skeletal muscle cells. These data together show the potential for the creation of a cell bank to be used as a cell source for muscle cell therapy and tissue engineering. For this purpose, we developed primary muscular cell cultures from biopsies of human male thigh muscle from a 16-week-old fetus and from donors of 13 and 30 years old. We show that fetal myogenic cells can be successfully isolated and expanded in vitro from human fetal muscle biopsies, and that fetal cells have higher growth capacities when compared to young and adult cells. We confirm lineage specificity by comparing fetal muscle cells to fetal skin and bone cells in vitro by immunohistochemistry with desmin and 5.1 H11 antibodies. For the feasibility of the cell bank, we ensured that fetal muscle cells retained intrinsic characteristics after 5 years cryopreservation. Finally, human fetal muscle cells marked with PKH26 were injected in normal C57BL/6 mice and were found to be present up to 4 days. In conclusion we estimate that a human fetal skeletal muscle cell bank can be created for potential muscle cell therapy and tissue engineering.
Collapse
Affiliation(s)
- Nathalie Hirt-Burri
- Pediatric Surgery Laboratory, University Hospital Lausanne, CHUV, CI/02/60, Lausanne, Switzerland.
| | | | | | | | | | | | | |
Collapse
|
5
|
Sciorati C, Galvez BG, Brunelli S, Tagliafico E, Ferrari S, Cossu G, Clementi E. Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci 2007; 119:5114-23. [PMID: 17158915 DOI: 10.1242/jcs.03300] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Muscular dystrophies are characterized by primary wasting of skeletal muscle for which no satisfactory therapy is available. Studies in animal models have shown that stem cell-based therapies may improve the outcome of the disease, and that mesoangioblasts are promising stem cells in this respect. The efficacy of mesoangioblasts in yielding extensive muscle repair is, however, still limited. We found that mesoangioblasts treated with nitric oxide (NO) donors and injected intra-arterially in alpha-sarcoglycan-null dystrophic mice have a significantly enhanced ability to migrate to dystrophic muscles, to resist their apoptogenic environment and engraft into them, yielding a significant recovery of alpha-sarcolgycan expression. In vitro NO-treated mesoangioblasts displayed an enhanced chemotactic response to myotubes, cytokines and growth factors generated by the dystrophic muscle. In addition, they displayed an increased ability to fuse with myotubes and differentiating myoblasts and to survive when exposed to cytotoxic stimuli similar to those present in the dystrophic muscle. All the effects of NO were cyclic GMP-dependent since they were mimicked by treatment with the membrane permeant cyclic-GMP analogue 8-bromo-cGMP and prevented by inhibiting guanylate cyclase. We conclude that NO donors exert multiple beneficial effects on mesoangioblasts that may be used to increase their efficacy in cell therapy of muscular dystrophies.
Collapse
MESH Headings
- Animals
- Apoptosis/drug effects
- Cell Differentiation/drug effects
- Cell Movement/drug effects
- Cells, Cultured
- Cyclic GMP/analogs & derivatives
- Cyclic GMP/pharmacology
- Gene Expression Profiling
- Immunohistochemistry
- Mesoderm/cytology
- Mesoderm/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Skeletal/drug effects
- Muscle, Skeletal/metabolism
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Muscular Dystrophy, Animal/genetics
- Muscular Dystrophy, Animal/therapy
- Nitric Oxide Donors/pharmacology
- Sarcoglycans/deficiency
- Sarcoglycans/genetics
- Stem Cell Transplantation
- Stem Cells/cytology
- Stem Cells/drug effects
- Stem Cells/metabolism
Collapse
Affiliation(s)
- Clara Sciorati
- Stem Cell Research Institute, H San Raffaele Scientific Institute, 20132, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
6
|
Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A 2006; 104:264-9. [PMID: 17182743 PMCID: PMC1765447 DOI: 10.1073/pnas.0608277104] [Citation(s) in RCA: 138] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death. There is currently no resolutive therapy. We have developed a treatment in which we combined the effects of nitric oxide with nonsteroidal antiinflammatory activity by using HCT 1026, a nitric oxide-releasing derivative of flurbiprofen. Here, we report the results of long-term (1-year) oral treatment with HCT 1026 of two murine models for limb girdle and Duchenne muscular dystrophies (alpha-sarcoglycan-null and mdx mice). In both models, HCT 1026 significantly ameliorated the morphological, biochemical, and functional phenotype in the absence of secondary effects, efficiently slowing down disease progression. HCT 1026 acted by reducing inflammation, preventing muscle damage, and preserving the number and function of satellite cells. HCT 1026 was significantly more effective than the corticosteroid prednisolone, which was analyzed in parallel. As an additional beneficial effect, HCT 1026 enhanced the therapeutic efficacy of arterially delivered donor stem cells, by increasing 4-fold their ability to migrate and reconstitute muscle fibers. The therapeutic strategy we propose is not selective for a subset of mutations; it provides ground for immediate clinical experimentation with HCT 1026 alone, which is approved for use in humans; and it sets the stage for combined therapies with donor or autologous, genetically corrected stem cells.
Collapse
Affiliation(s)
- Silvia Brunelli
- *Department of Experimental Medicine, University of Milano–Bicocca, 20052 Monza, Italy
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
| | - Clara Sciorati
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
| | - Giuseppe D'Antona
- Department of Experimental Medicine, University of Pavia, 27100 Pavia, Italy
| | - Anna Innocenzi
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
| | - Diego Covarello
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
| | - Beatriz G. Galvez
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
| | - Cristiana Perrotta
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
- Department of Preclinical Sciences, University of Milano, 20157 Milan, Italy
| | - Angela Monopoli
- Nicox Research Institute, Via Ariosto 21, 20091 Bresso, Italy
| | - Francesca Sanvito
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
| | - Roberto Bottinelli
- Department of Experimental Medicine, University of Pavia, 27100 Pavia, Italy
| | - Ennio Ongini
- Nicox Research Institute, Via Ariosto 21, 20091 Bresso, Italy
| | - Giulio Cossu
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
- Department of Biology, University of Milano, 20130 Milan, Italy
- **To whom correspondence may be addressed at:
Stem Cell Research Institute, H. San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy. E-mail:
or
| | - Emilio Clementi
- San Raffaele Scientific Institute, Stem Cell Research Institute, Via Olgettina 58, 20132 Milan, Italy
- E. Medea Scientific Institute, 23842 Bosisio Parini, Italy; and
- Department of Preclinical Sciences, University of Milano, 20157 Milan, Italy
- **To whom correspondence may be addressed at:
Stem Cell Research Institute, H. San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy. E-mail:
or
| |
Collapse
|
7
|
Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 2006; 176:9-15. [PMID: 16725212 DOI: 10.1016/j.jneuroim.2006.03.026] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2005] [Revised: 03/29/2006] [Accepted: 03/29/2006] [Indexed: 11/17/2022]
Abstract
Inflammatory/immune reactions against muscle cells are responsible for the damage in idiopathic inflammatory myopathies. We investigated the role of IL-6, a cytokine known to contribute to local leukocyte accumulation, in a model of myosin-induced experimental myositis. After injection of rabbit myosin in CFA/pertussis toxin, normal mice develop clinically evident muscle deficit and damage, as demonstrated by myofiber necrosis and leukocyte infiltration, while IL-6-deficient mice have no clinical or histological signs of muscle damage. This study evidences that selective deficiency of IL-6 directly or indirectly hinders the local inflammatory response and its harmful effects in this model of muscle damage.
Collapse
Affiliation(s)
- Flavia Scuderi
- Institute of General Pathology, Catholic University, Largo F. Vito 1, 00168 Rome, Italy
| | | | | | | | | |
Collapse
|
8
|
Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E, Cornelio F, Mantegazza R, Confalonieri P. Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 2006; 175:77-86. [PMID: 16647144 DOI: 10.1016/j.jneuroim.2006.03.005] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2005] [Revised: 02/14/2006] [Accepted: 03/06/2006] [Indexed: 11/16/2022]
Abstract
Irreversible connective tissue proliferation in muscle is a pathological hallmark of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease due to lack of the sarcolemmal protein dystrophin. Focal release of transforming growth factor-beta1 (TGF-beta1) is involved in fibrosis development. Murine muscular dystrophy (mdx) is genetically homologous to DMD and histopathological alterations comparable to those in DMD muscles occur in diaphragm of older mdx mice. To investigate the early development of fibrosis and TGF-beta1 involvement, we assessed diaphragms in 6-36-week-old mdx and C57/BL6 (control) mice for fibrosis, and used real-time PCR and ELISA to determine TGF-beta1 expression. Significantly greater fibrosis and TGF-beta1 expression were found in mdx from the 6th week. Mice treated with neutralizing antibody against TGF-beta1 had lower levels of TGF-beta1 protein, reduced fibrosis, unchanged muscles fiber degeneration/regeneration, but increased inflammatory cells (CD4+lymphocytes). These data demonstrate early and progressive fibrosis in mdx diaphragm accompanied by TGF-beta1 upregulation. Reduction of TGF-beta1 appears promising as a therapeutic approach to muscle fibrosis, but further studies are required to evaluate long term effects of TGF-beta1 immunomodulation on the immune system.
Collapse
Affiliation(s)
- Francesca Andreetta
- Department of Neuroimmunology and Neuromuscular Diseases, National Neurological Institute Carlo Besta, via Celoria 11, 20133 Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Vignaud A, Hourdé C, Torres S, Caruelle JP, Martelly I, Keller A, Ferry A. Functional, cellular and molecular aspects of skeletal muscle recovery after injury induced by snake venom from Notechis scutatus scutatus. Toxicon 2005; 45:789-801. [PMID: 15804529 DOI: 10.1016/j.toxicon.2005.02.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2004] [Indexed: 11/21/2022]
Abstract
We have analysed the rate and ultimate extent of muscle functional recovery after snake venom-induced myotoxicity, as well as the relationships between functional, biochemical and structural indices of recovery. We also compared the effects of various injuries leading to muscle necrosis, loss of innervation/vasculature and/or precursors of muscle cells (pmc). We found that several parameters of rat soleus muscle such as maximal isometric force, slow myosin heavy chain, and citrate synthase, were fully and rapidly restored within 6 weeks after treatment with snake Notechis scutatus venom (im, 2 microg/muscle). In contrast, some muscle contractile properties (degree of tetanic fusion, fatigue resistance...) were not fully recovered even by 12 weeks after venom treatment. However, when compared to other injuries, recovery 3 weeks after venom treatment, was better than that observed after severing the terminal nerve and accompanying vessels and after cryodamage known to kill pmc. In conclusion, our studies demonstrate that-contrary to what is commonly believed -- muscle treated by myotoxic agent does not recover rapidly and fully. However, the degree or rate of muscle recovery after snake venom treatment was much better when compared to other types of injury. In addition, histological and biochemical parameters cannot be used as such to easily predict functional recovery following injury.
Collapse
Affiliation(s)
- A Vignaud
- Laboratoire d' étude sur la croissance cellulaire, la régénération et la réparation tissulaires, UMR 7149 CNRS, Faculté des Sciences, Université Paris 12, Créteil, France
| | | | | | | | | | | | | |
Collapse
|
10
|
Skuk D, Roy B, Goulet M, Chapdelaine P, Bouchard JP, Roy R, Dugré FJ, Lachance JG, Deschênes L, Hélène S, Sylvain M, Tremblay JP. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 2004; 9:475-82. [PMID: 15038390 DOI: 10.1016/j.ymthe.2003.11.023] [Citation(s) in RCA: 146] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Three Duchenne muscular dystrophy (DMD) patients received injections of myogenic cells obtained from skeletal muscle biopsies of normal donors. The cells (30 x 10 (6)) were injected in 1 cm3 of the tibialis anterior by 25 parallel injections. We performed similar patterns of saline injections in the contralateral muscles as controls. The patients received tacrolimus for immunosuppression. Muscle biopsies were performed at the injected sites 4 weeks later. We observed dystrophin-positive myofibers in the cell-grafted sites amounting to 9 (patient 1), 6.8 (patient 2), and 11% (patient 3). Since patients 1 and 2 had identified dystrophin-gene deletions these results were obtained using monoclonal antibodies specific to epitopes coded by the deleted exons. Donor dystrophin was absent in the control sites. Patient 3 had exon duplication and thus specific donor-dystrophin detection was not possible. However, there were fourfold more dystrophin-positive myofibers in the cell-grafted than in the control site. Donor-dystrophin transcripts were detected by RT-PCR (using primers reacting with a sequence int eh deleted exons) only in the cell-grafted sites in patients 1 and 2. Dystrophin transcripts were more abundant in the cell-grafted than in the control site in patient 3. Therefore, significant dystrophin expression can be obtained in teh skeletal muscles of DMD patients following specific conditions of cell delivery and immunosuppression.
Collapse
Affiliation(s)
- Daniel Skuk
- Human Genetic Research Unit, laval Unibersity Hospital Center, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Skeletal muscles are composed of fibres of different types, each type being identified by the isoform of myosin heavy chain which is expressed as slow 1, fast 2A, fast 2X, and fast 2B. Slow fibres are resistant to fatigue due to their highly oxidative metabolism whereas 2X and 2B fibres are easily fatiguable and fast 2A fibres exhibit intermediate fatigue resistance. Slow fibres and fast fibres are present in equal proportions in the adult human diaphragm while intercostal muscles contain a higher proportion of fast fibres. A small fibre size, abundance of capillaries, and a high aerobic oxidative enzyme activity are typical features of diaphragm fibres and give them the resistance to fatigue required by their continuous activity. Because of their fibre composition, intercostal muscles are less resistant to fatigue. The structural and functional characteristics of respiratory muscle fibres are not fixed, however, and can be modified in response to several physiological and pathological conditions such as training (adaptation to changes in respiratory load), adaptation to hypoxia, age related changes, and changes associated with respiratory diseases. The properties of respiratory muscle fibres can also be modified by pharmacological agents such as beta2 agonists and corticosteroids used for the treatment of respiratory diseases.
Collapse
Affiliation(s)
- B Polla
- Hospital S Biagio, Department of Pneumology, Alessandria, Italy.
| | | | | | | |
Collapse
|
12
|
Abstract
1. Repeated activity of skeletal muscle causes a variety of changes in its properties: muscles become weaker with intense use (fatigue), may feel sore and weak after repeated contractions involving stretch and can degenerate in some disease conditions. The present review considers the role of early ionic changes in the development of each of these conditions. 2. Single fibre preparations of mouse muscle were used to measure ionic changes following activity induced changes in function. Single fibres were dissected with intact tendons and stimulated to produce force. Fluorescent indicators were microinjected into the fibres to allow simultaneous ionic measurements with determination of mechanical performance. 3. One theory to explain muscle fatigue is that fatigue is caused by the accumulation of lactic acid, producing an intracellular acidosis that inhibits the myofibrillar proteins. In contrast, we found that during repeated tetani there was little or no pH change, but that failure of calcium release was a major contributor to fatigue. Currently, it is proposed that precipitation of calcium and phosphate in the sarcoplasmic reticulum contributes to the failure of calcium release. 4. Muscles can be used to shorten and produce force or they can be used to de-accelerate loads (stretched or eccentric contractions). One day after intense exercise involving stretched contractions, muscles are weak, sore and tender, and this damage can take a week to recover. In this condition, sarcomeres are disorganized and there are increases in resting intracellular Ca2+ and Na+. Recently, we demonstrated that the elevation of Na+ occurs through a stretch-activated channel that can be blocked by either gadolinium or streptomycin. Preventing the increase in [Na+]i with gadolinium also prevented part of the muscle weakness after stretched contractions. 5. Duchenne muscular dystrophy is a lethal degenerative disease of muscles in which the protein dystrophin is absent. Dystrophic muscles are more susceptible to stretch-induced muscle damage and the stretch-activated channel seems to be one pathway for the increases in intracellular Ca2+ and Na+ that are a feature of this disease. We have shown recently that blockers of the stretch-activated channel can minimize some of the short-term damage in muscles from the mdx mouse, which also lacks dystrophin. Currently, we are testing whether blockers of the stretch-activated channels given systemically to mdx mice can protect against some features of the disease.
Collapse
Affiliation(s)
- D G Allen
- School of Biomedical Sciences and Institute for Biomedical Research, University of Sydney, Sydney, New South Wales, Australia.
| |
Collapse
|
13
|
Yeung EW, Head SI, Allen DG. Gadolinium reduces short-term stretch-induced muscle damage in isolated mdx mouse muscle fibres. J Physiol 2004; 552:449-58. [PMID: 14561828 PMCID: PMC2343387 DOI: 10.1113/jphysiol.2003.047373] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Duchenne muscular dystrophy is a lethal muscle disease caused by absence of the protein dystrophin which is part of a glycoprotein complex located on the intracellular surface of the surface membrane. The precise function of dystrophin and the reason why its absence causes severe muscle damage are unclear. Stretch-induced muscle damage is well recognised in normal muscle and is more severe in muscles from animals lacking dystrophin (mdx mice). It has been proposed that stretch-induced damage underlies the progression of damage in muscular dystrophy. In the present study we confirm that single fibres from mdx muscle are more susceptible to stretch-induced damage and show that there is an associated rise in intracellular sodium concentration ([Na+]i) which is greater than in wild-type mice. We show that this rise in [Na+]i can be prevented by Gd3+, which is an established blocker of stretch-activated channels. mdx fibres have a higher than normal resting [Na+]i and this is also reduced by Gd3+. If Gd3+ is applied over the period in which [Na+]i rises following stretched contraction, it prevents one component of the reduced force. The other component of reduced force is caused by inhomogeneity of sarcomeres and can be minimised by stretching the muscle to its new optimum length. These experiments show that part of the short-term damage caused by stretch in mdx fibres can be prevented by blocking stretch-activated channels.
Collapse
Affiliation(s)
- Ella W Yeung
- Institute for Biomedical Research and Department of Physiology, University of Sydney F13, NSW 2006, Australia
| | | | | |
Collapse
|
14
|
Lafreniere JF, Mills P, Tremblay JP, El Fahime E. GROWTH FACTORS IMPROVE THE IN VIVO MIGRATION OF HUMAN SKELETAL MYOBLASTS BY MODULATING THEIR ENDOGENOUS PROTEOLYTIC ACTIVITY. Transplantation 2004; 77:1741-7. [PMID: 15201676 DOI: 10.1097/01.tp.0000131175.60047.eb] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND A main technological problem related to the clinical application of myoblast transplantation is the poor migration of transplanted cells. In this study, we investigated a new physiologic approach that consists of coinjecting motogenic factors insulin growth factor (IGF)-1 or basic fibroblast growth factor (bFGF) to enhance the migration of human skeletal myoblasts. Among the different ways by which those factors can induce the cell migration processes, we investigated their capacity to enhance cell endogenous proteolytic activity that will help transplanted cells to migrate through the extracellular matrix. METHODS In vitro, myoblasts were coincubated with bFGF or IGF-1. Growth factors effects on cell migration were evaluated using invasion chambers, and their effects on proteolytic systems were evaluated by zymography, Western blot, and reverse transcription polymerase chain reaction. In vivo, myoblasts were coinjected with growth factors and the intramuscular migration capacity was assessed using the microtube technique. RESULTS In vitro, the presence of IGF-1 or bFGF significantly enhanced the expression of the gelatinase matrix metalloproteinase-9 and focalized the fibrinolytic system activity at the cell membrane. In vitro and in vivo, both bFGF and IGF-1 showed strong chemokinetic potentials and improved the migration of human myoblasts. Moreover, the implication some proteinases in the in vivo enhanced migration was confirmed using specific inhibitors (BB94 or amiloride). CONCLUSIONS These results suggest that IGF-1 or bFGF coinjection with human myoblasts increased their proteolytic activities and consequently their migratory capacity. This study may help to develop approaches that will reduce the number of injection sites for the treatment of Duchenne muscular dystrophy patients.
Collapse
Affiliation(s)
- Jean Francois Lafreniere
- Unité de Recherche en Génétique Humaine, Centre Hospitalier de l'Université Laval, Ste-Foy, Québec, Canada
| | | | | | | |
Collapse
|
15
|
Abstract
Muscular dystrophies are a heterogeneous group of inherited disorders characterized by progressive muscle wasting and weakness. Majority of genes and their protein products responsible for the dystrophies have been identified in recent years. Using molecular studies, now it is possible to establish a precise diagnosis, provide prognosis, detect preclinical cases, identify carriers, and offer prenatal diagnostic testing. Molecular genetic approaches also seem to offer the best prospect for developing effective treatments in the future.
Collapse
Affiliation(s)
- Monisha Mukherjee
- Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, India
| | | |
Collapse
|
16
|
Wicklund MP, Mendell JR. The limb girdle muscular dystrophies: our ever-expanding knowledge. J Clin Neuromuscul Dis 2003; 5:12-28. [PMID: 19078718 DOI: 10.1097/00131402-200309000-00003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The limb girdle muscular dystrophies (LGMDs) represent a genetically diverse group of disorders. Currently, chromosomal loci are known for at least 5 autosomal-dominant and 10 autosomal-recessive subgroups. In 13 of these, recognized genes and protein products generate an assortment of phenotypes, some unique and many overlapping. In some disorders, novel clinical features are sufficiently distinct so as to proffer clues to the diagnosis of a specific LGMD subtype. An armamentarium of laboratory tools is required to confirm specific subtypes of LGMD. These might only be available in neuromuscular centers specializing in this form of dystrophy. Currently, supportive therapy is the predominant means of treatment, but further understanding of unique pathogenic mechanisms holds promise for the future.
Collapse
Affiliation(s)
- Matthew P Wicklund
- From the Department of Neurology, Wilford Hall Medical Center, Lackland Air Force Base, Texas (Dr Wicklund); and the Department of Neurology, The Ohio State University, Columbus, Ohio (Dr Mendell)
| | | |
Collapse
|
17
|
Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, Pellegrino MA, Barresi R, Bresolin N, De Angelis MGC, Campbell KP, Bottinelli R, Cossu G. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301:487-92. [PMID: 12855815 DOI: 10.1126/science.1082254] [Citation(s) in RCA: 507] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Preclinical or clinical trials for muscular dystrophies have met with modest success, mainly because of inefficient delivery of viral vectors or donor cells to dystrophic muscles. We report here that intra-arterial delivery of wild-type mesoangioblasts, a class of vessel-associated stem cells, corrects morphologically and functionally the dystrophic phenotype of virtually all downstream muscles in adult immunocompetent alpha-sarcoglycan (alpha-SG) null mice, a model organism for limb-girdle muscular dystrophy. When mesoangioblasts isolated from juvenile dystrophic mice and transduced with a lentiviral vector expressing alpha-SG were injected into the femoral artery of dystrophic mice, they reconstituted skeletal muscle in a manner similar to that seen in wild-type cells. The success of this protocol was mainly due to widespread distribution of donor stem cells through the capillary network, a distinct advantage of this strategy over previous approaches.
Collapse
MESH Headings
- Animals
- Blood Vessels/cytology
- Blood Vessels/embryology
- Cell Differentiation
- Cell Line
- Cell Movement
- Cytoskeletal Proteins/genetics
- Cytoskeletal Proteins/metabolism
- Dystrophin/metabolism
- Endothelium, Vascular/physiology
- Female
- Femoral Artery
- Genetic Vectors
- Lentivirus/genetics
- Locomotion
- Male
- Membrane Glycoproteins/genetics
- Membrane Glycoproteins/metabolism
- Mesoderm/cytology
- Mice
- Mice, Knockout
- Mice, Transgenic
- Muscle Contraction
- Muscle Fibers, Skeletal/cytology
- Muscle Fibers, Skeletal/physiology
- Muscle, Skeletal/cytology
- Muscle, Skeletal/metabolism
- Muscle, Skeletal/pathology
- Muscle, Skeletal/physiology
- Muscular Dystrophy, Animal/metabolism
- Muscular Dystrophy, Animal/pathology
- Muscular Dystrophy, Animal/therapy
- Regeneration
- Sarcoglycans
- Stem Cell Transplantation
- Stem Cells/physiology
- Transfection
Collapse
Affiliation(s)
- Maurilio Sampaolesi
- Stem Cell Research Institute, H. S. Raffaele, Via Olgettina 58, 20132 Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|